Disclosures: Elizabeth Jensen: Nothing to Disclose, Jonathan Young: Nothing to Disclose, Mark Chicote: Nothing to Disclose, Edward List: Nothing to Disclose, Kathleen Corey: Theratechnology: Consultant, Intercept: Advisor, Medscape: Speaking and Teaching, Sagimet: Advisor, John Kopchick: Nothing to Disclose, Darlene Berryman: Nothing to Disclose, Laura Dichtel: Nothing to Disclose 1054 "FROM ABSCESS TO TUMOR: TRACKING THE PREVALENCE OF COLON CANCER AMONG PYOGENIC LIVER ABSCESS PATIENTS (2016-2020)" Khalid Aloum 1 Amr Dokmak 2 Wendy Tatiana Garzon-Siatoya 1 Abdellatif Ismail 1 Camelia Ciobanu 2 Jeeva Jaganathan 3 Praneeth Bandaru 2 Ali Wakil 2 Arnold Nongmoh Forlemu 2 Vijay Bhaskar Reddy Gayam 4 Vikash Kumar 2 Raissa Nana Sede Mbakop 1 Lisnaldy Ramirez 1 Manasa Ginjupalli 2 Denzil Etienne 2 Nithan Narendra 5 Madhavi Reddy 2 , 1 St Barnabas Hospital, 2 The Brooklyn Hospital Center, 3 Saint Vincent Catholic Medical Centers, 4 State University of New York-Downstate, 5 St
10.1186/s12935-020-01232-9 Cancer Cell Int
Bromantane Bromantane , sold under the brand name Ladasten , is an atypical central nervous system (CNS) stimulant and anxiolytic drug of the adamantane family that is related to amantadine and memantine
Accordingly, studying and understanding the interaction of antibiotics, antibiotic NPs, or NPs loaded with antibiotic drugs with biofilms is a significant milestone toward effectively suppressing biofilm-associated infections [218]
